Talem Therapeutics

Empowering Through Excellence

Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology,  inflammation, and rare/specialty diseases.

With direct access to world-class, expedited and end-to-end technologies in the antibody discovery and development process, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships. For further information contact bd@talemtherapeutics.com.

About Us

Empowering Teams, Transforming Therapeutics

Talem Therapeutics (Talem) is a wholly owned subsidiary of ImmunoPrecise Antibodies (IPA) and is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies to target multiple disease indications.

Using the proprietary antibody discovery platforms and innovative technologies housed at ImmunoPrecise Antibodies and U-Protein Express (an IPA company), Talem aims to accelerate novel, high-value, therapeutic antibody treatments to the clinic.

Transgenic
Animals at Talem

We have optimized our powerful, custom, species-agnostic technologies for use with transgenic animal platforms to enable the discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy as well as the lowest immunogenicity. The ability to select very specific, “needle-in-a-haystack” human antibodies via this advanced combination offers an entirely new avenue of therapeutic antibody discovery. Talem is the only CRO affiliate globally to offer these services as a partnership with OmniAb® transgenic (www.omniab.com) animals using their own license.

The PolyTope™ Advantage

Talem Therapeutics has been actively involved in COVID-19 research since January 2020. Monoclonal antibodies were derived from several animal species, including transgenic OmniRat® rodents, rabbits, human and llama, to access a broad epitope coverage. We exploit multiple in vivo and in vitro discovery platforms (B cell cloning, hybridoma, and phage display) and multiple antibody formats (IgG, scFv, and VHH) to increase the chances of finding clones with unique/rare epitopes and facilitate their reformulation into bispecifics or other modular formats. Our multinational teams in North America and Europe have developed a rich SARS-CoV-2 antibody portfolio with deep epitope and functional diversity.

>The Polytope™ Advantage

Partner with Talem

Talem Therapeutics is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeted toward any disease indication.

With direct access to world-class, expedited and end-to-end technologies in antibody discovery, characterization, manufacturing and engineering, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships.